Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 2/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.43 |
| ▸ | FURIN | P09958 | 1/20 | 0.43 |
| ▸ | TSLP | Q969D9 | 9/20 | 0.42 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 2/20 | 0.40 |
| ▸ | MC5R | P33032 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
| ▸ | MC1R | Q01726 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206279 | 0.95 | SIRT2 (0.42) | CTSGKLKB1TSLPSIRT2SIRT1 | |
| SCHEMBL20206177 | 0.92 | MC4R (0.40) | CTSGKLKB1PLAUSIRT2SIRT1 | |
| SCHEMBL20206181 | 0.92 | SIRT2 (0.41) | KLKB1PLAUSIRT2SIRT1SIRT3 | |
| SCHEMBL20206207 | 0.91 | KEAP1 (0.40) | CTSGSIRT2SIRT1SIRT3MC4R | |
| SCHEMBL20206174 | 0.89 | OPRM1 (0.44) | — | |
| SCHEMBL20206278 | 0.88 | MEN1 (0.40) | CTSGMC4RMC3R | |
| SCHEMBL19473904 | 0.86 | MC4R (0.46) | CTSGFURINTSLPSIRT2SIRT1 | |
| SCHEMBL19474002 | 0.86 | SIRT2 (0.48) | FURINTSLPSIRT2SIRT1SIRT3 | |
| SCHEMBL20206282 | 0.85 | MC4R (0.55) | TSLPMC4RMC1R | |
| SCHEMBL20206173 | 0.85 | TSLP (0.39) | CTSGTSLPMC4RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | PALATIN TECHNOLOGIES INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | PALATIN TECHNOLOGIES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | PALATIN TECHNOLOGIES INC (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | MC1R, MC3R, MC4R | CTSG 2450/4885KLKB1 2825/4885FURIN 1061/4885 |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | CTSG 844/4885KLKB1 234/4885FURIN 400/4885 |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | MC3R, MC1R, MC2R | CTSG 844/4885KLKB1 234/4885FURIN 400/4885 |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | MC1R, MC3R, MC4R | CTSG 2450/4885KLKB1 2825/4885FURIN 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.